SCHEMBL277386

SCHEMBL277386

CCC(C)C[N]CC(C)CC

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1797527 0.82
SCHEMBL29939810 0.79 TSHR (0.33) TSHR
SCHEMBL6050093 0.78
SCHEMBL2397547 0.78
SCHEMBL15047767 0.76
SCHEMBL14678819 0.76
SCHEMBL11932972 0.76
SCHEMBL8542693 0.76
SCHEMBL6464261 0.73
SCHEMBL8343474 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024117205-A1 BICYCLIC PYRIDINE DERIVATIVE AND SALT THEREOF, AND HARMFUL ORGANISM CONTROL AGENT CHARACTERIZED BY CONTAINING SAID DERIVATIVE OR SALT THEREOF AS ACTIVE INGREDIENT 北興化学工業株式会社 2024-06-06 WO disclosed
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-10-19 US disclosed
US-11731971-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2023-08-22 US disclosed
US-11548984-B2 Light- or heat-curing method and curable resin composition FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2023-01-10 US disclosed
US-20220348578-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2022-11-03 US disclosed
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-12-02 US disclosed
US-11117896-B2 Processes for preparing a diazabicyclooctane compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2021-09-14 US disclosed
EP-3067355-B1 CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION METHOD FOR CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE MEIJI SEIKA PHARMA CO LTD (JP) 2020-12-16 EP disclosed
US-10774062-B2 Photocuring method, compound and composition used therein FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2020-09-15 US disclosed
EP-3327002-B1 ACID-RESISTANT BASE AND/OR RADICAL GENERATOR, AND CURABLE RESIN COMPOSITION CONTAINING SAID BASE AND/OR RADICAL GENERATOR FUJIFILM WAKO PURE CHEMICAL CORP (JP) 2020-08-19 EP disclosed
US-5773172-A SOLVENT AND BINDER SOLUBILITY MITSUI TOATSU CHEMICALS, INC. (JP) 1998-06-30 US disclosed
EP-0564237-B1 Preparation of color filter and photo-setting resin therefor MITSUI TOATSU CHEMICALS (JP) 1998-03-11 EP disclosed
EP-0818512-A1 Quinoline derivative and use of same MITSUI TOATSU CHEMICALS, Inc. (JP) 1998-01-14 EP disclosed
US-5695911-A CONTAINING PHTHALOCYANINE COMPOUND MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1997-12-09 US disclosed
US-5482804-A Resin composition for color filter MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1996-01-09 US disclosed
EP-0633296-A1 Novel dyestuffs and their use MITSUI TOATSU CHEMICALS, Inc. (JP) 1995-01-11 EP disclosed
US-5380842-A Color filters MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1995-01-10 US disclosed
EP-0564237-A2 Preparation of color filter and photo-setting resin therefor MITSUI TOATSU CHEMICALS, Inc. (JP) 1993-10-06 EP disclosed
EP-0562832-A1 Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use SANKYO COMPANY LIMITED (JP) 1993-09-29 EP disclosed
EP-0519423-A2 Phthalocyanine compounds and usage thereof MITSUI TOATSU CHEMICALS, Inc. (JP) 1992-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731971-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 TSHR 1888/4885
US-20220348578-A1 CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF CCNA1, RCC1, DDT TSHR 3422/4885
US-10774062-B2 Photocuring method, compound and composition used therein ESD, TMT1A, PAM TSHR 4741/4885
US-20210371419-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 TSHR 1888/4885
US-20230331724-A1 PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND FN1, BMP1, AZI2 TSHR 1888/4885
US-11117896-B2 Processes for preparing a diazabicyclooctane compound FN1, BMP1, AZI2 TSHR 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.